Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
66 participants
INTERVENTIONAL
2018-04-26
2022-03-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of a New Bone Conduction Hearing System to a Osteo-integrated Bone Conduction Hearing Aid on a Softband
NCT03541967
Post-market Clinical Follow-up of a Magnetic Bone Conduction Implant (Cochlear Baha Attract System)
NCT02022085
Evaluation of the Effectiveness of Bone-anchored Hearing Aids (Baha)
NCT01264510
Audiological Benefit and Quality of Life With Two Bone Conduction Systems: ADHEAR vs. Contact Mini
NCT03746548
Audiological Benefit and Improved Quality of Life With Two Bone Conduction Systems: ADHEAR vs. Bonebridge in Experienced Users
NCT03766152
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Single-Sided Deafness Adult (Aim1) Group
Adult participants with single-sided deafness and are experienced bone conduction device users (6 months minimum of bone conduction device use and no intermittent use within the last 2 weeks) with an abutment implant will be provided with the Adhear system for 2 weeks (plus up to 90 days).
Adhear Bone Conduction System
Non-invasive bone conduction hearing device using adhesive
Conductive Hearing Loss Adult (Aim 2) Group
Adult participants with conductive hearing loss and are experienced bone conduction device users (6 months minimum of bone conduction device use and no intermittent use within the last 2 weeks) with an abutment implant will be provided with the Adhear system for 2 weeks (plus up to 90 days).
Adhear Bone Conduction System
Non-invasive bone conduction hearing device using adhesive
Adhear followed by BAHA (Aim 3) Group
Pediatric participants (aged 5-17 years) and their parents with conductive hearing loss or single-sided deafness who have not previously used a bone conduction device, will be provided with the Adhear system for 3 weeks (plus up to 90 days) followed by bone anchored hearing aid (BAHA) for another 3 weeks (plus up to 90 days).
Adhear Bone Conduction System
Non-invasive bone conduction hearing device using adhesive
Bone anchored hearing aid (BAHA)
Non-invasive bone conduction hearing device using a headband
BAHA followed by Adhear (Aim 3) Group
Pediatric participants (aged 5-17 years) and their parents with conductive hearing loss or single-sided deafness who have not previously used a bone conduction device, will be provided with the BAHA system for 3 weeks (plus up to 90 days) followed by Adhear for another 3 weeks (plus up to 90 days).
Adhear Bone Conduction System
Non-invasive bone conduction hearing device using adhesive
Bone anchored hearing aid (BAHA)
Non-invasive bone conduction hearing device using a headband
Pediatric Unilateral Conductive Hearing Loss (Aim 3a) Group
Pediatric participants (aged 2-17 years) and their parents with unilateral conductive hearing loss and are experienced bone conduction device users (6 months minimum of bone conduction device use) on a headband will be provided with the Adhear system for 2 weeks (plus up to 90 days).
Adhear Bone Conduction System
Non-invasive bone conduction hearing device using adhesive
Pediatric Bilateral Conductive Hearing Loss (Aim 3b) Group
Pediatric participants (aged 2-17 years) and their parents with bilateral conductive hearing loss and are experienced bone conduction device users (6 months minimum of bone conduction device use) on a headband will be provided with the Adhear system. Participants who are fitted bilaterally will receive 2 Adhear systems (one for each ear) for 2 weeks (plus up to 90 days) at Visit 1. Participants who are fitted unilaterally will receive 1 Adhear system for 2 weeks (plus up to 90 days) at Visit 1, afterwards, will be fitted bilaterally at Visit 2 and receive the Adhear system for both ears for another 2 weeks (plus up to 90 days) for a total of 4 weeks (plus up to 180 days).
Adhear Bone Conduction System
Non-invasive bone conduction hearing device using adhesive
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Adhear Bone Conduction System
Non-invasive bone conduction hearing device using adhesive
Bone anchored hearing aid (BAHA)
Non-invasive bone conduction hearing device using a headband
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Adult English speaking patients who are experienced users of Bone Anchored Implants (BAIs) for the indication of either single sided deafness or conductive hearing loss.
* Experienced will be defined as greater than 6 months of device use and no intermittent function of the device within 2 weeks of enrollment.
* Subjects will be limited to those who have normal hearing by bone conduction defined as a pure tone average of 25 dBHL or better at 500, 1000, 2000, \& 3000 Hz in at least one ear.
Aim 3:
* English speaking children 5 to 17 years of age and their primary guardian who present to the clinic for treatment by BAI on a headband device for the indications of single sided deafness or conductive hearing loss.
* Subjects will be limited to those who have no prior use of a BAI or bone conduction hearing device, normal hearing by bone conduction defined as a pure tone average of 25 dBHL or better at 500, 1000, 2000, \& 3000 Hz in at least one ear. For those children where this cannot be definitively established, children will be included who display clinical signs of normal bone conduction hearing beyond a reasonable doubt and may include such evidence as (but not limited to): auditory brainstem response, speech awareness thresholds, visual reinforcement audiometry, conditioning play audiometry, CT scans, etc.)
Aim 3 a \& b:
* Pediatric bilateral or unilateral conductive hearing loss patients who are between the ages of 2 and 17 years of age
* Pediatric participants who are currently managed by the University of Miami with a bone conduction device attached to a softband.
Exclusion Criteria
* Non-English speakers
* Participants reporting allergies to adhesives or highly reactive skin.
Aim 3:
* Pediatric participants who are non-English speakers.
* Children who have previous experience with a BAI or bone conduction hearing device will not be included for study.
* Pediatric participants reporting allergies to adhesives or highly reactive skin.
Aims 3a \& 3b:
* Pediatric participants who are non-English speakers.
* Pediatric participants reporting allergies to adhesives or highly reactive skin.
2 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Med-El Corporation
INDUSTRY
University of Miami
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hillary A Snapp
Associate Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hillary Snapp, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Miami
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Miami Department of Otolaryngology
Miami, Florida, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20161220
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.